A New Antibody for Targeting Activated Macrophages in Rheumatoid Arthritis
Author Information
Author(s): Feng Yang, Shen Jiayin, Streaker Emily D, Lockwood Michael, Zhu Zhongyu, Low Philip S, Dimitrov Dimiter S
Primary Institution: National Institutes of Health
Hypothesis
Can a folate receptor beta-specific human monoclonal antibody be developed to target activated macrophages in rheumatoid arthritis and other autoimmune diseases?
Conclusion
The m909 antibody selectively binds to FRβ and can mediate the elimination of FRβ positive cells, making it a potential therapeutic agent for rheumatoid arthritis and related conditions.
Supporting Evidence
- m909 binds specifically to FRβ and not to FRα.
- The antibody can mediate antibody-dependent cell-mediated cytotoxicity in FRβ positive cells.
- m909 can select activated macrophages from synovial fluid of arthritis patients.
Takeaway
Scientists created a special antibody that can find and help destroy bad cells in people with rheumatoid arthritis. This could help treat the disease better.
Methodology
The study involved producing a recombinant FRβ protein, isolating a specific antibody (m909) from a human phage display library, and testing its binding and cytotoxic effects on FRβ positive cells.
Limitations
The study primarily focused on in vitro assays and may require further validation in clinical settings.
Participant Demographics
Patients with rheumatoid arthritis from Indiana University Health Arnett.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website